Current management and future perspectives of metastatic renal cell carcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current management and future perspectives of metastatic renal cell carcinoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF UROLOGY
Volume 21, Issue 9, Pages 847-855
Publisher
Wiley
Online
2014-05-27
DOI
10.1111/iju.12502
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria
- (2013) Nils Kroeger et al. CANCER
- PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma
- (2013) James Brugarolas CANCER JOURNAL
- Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
- (2013) A. A. Hakimi et al. CLINICAL CANCER RESEARCH
- A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma
- (2013) Lauren C. Harshman et al. Clinical Genitourinary Cancer
- Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy
- (2013) Rana R. McKay et al. EUROPEAN UROLOGY
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients
- (2013) Mhd Y. Al-Marrawi et al. Targeted Oncology
- Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients
- (2013) Sei Naito et al. UROLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) B. Escudier et al. ANNALS OF ONCOLOGY
- Evidence-Based Clinical Practice Guideline for Renal Cell Carcinoma: The Japanese Urological Association 2011 update
- (2012) Tomoaki Fujioka et al. INTERNATIONAL JOURNAL OF UROLOGY
- Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin
- (2012) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
- (2011) Ana M. Molina et al. CANCER
- Survival after complete surgical resection of multiple metastases from renal cell carcinoma
- (2011) Angela L. Alt et al. CANCER
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy
- (2010) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- (2010) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- (2010) Jose A. Karam et al. JOURNAL OF UROLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
- (2008) Jacob A. Klapper et al. CANCER
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
- (2008) Kiran Gupta et al. CANCER TREATMENT REVIEWS
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma
- (2008) Scott E. Eggener et al. JOURNAL OF UROLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started